Document:

EX-4.1

 Exhibit 4.1 
  

 
 THE AES CORPORATION 

as Issuer 
 AND 

DEUTSCHE BANK TRUST COMPANY AMERICAS 

as Trustee 
  

 
 TWENTY-FOURTH
SUPPLEMENTAL INDENTURE 
 Dated as of March 15, 2018 

TO 
 SENIOR INDENTURE 

Dated as of December 8, 1998 
  

 
 5.500% Senior
Notes due 2024 
  
  

 TWENTY-FOURTH SUPPLEMENTAL INDENTURE 

The TWENTY-FOURTH SUPPLEMENTAL INDENTURE, is dated as of this 15th day of March, 2018 (the “Supplemental Indenture”), between
THE AES CORPORATION, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter sometimes referred to as the “Company”), and DEUTSCHE BANK TRUST COMPANY AMERICAS, a national banking association,
as trustee (hereinafter referred to as the “Trustee”), as successor trustee to WELLS FARGO BANK, N.A. 
 W I T N E S S E T
H: 
 WHEREAS, the Company entered into a Senior Indenture dated as of December 8, 1998 (the “Senior Indenture”)
between the Company and the Trustee to provide for the future issuance of its senior debentures, notes or other evidences of indebtedness (collectively, the “Securities”), said Securities to be issued from time to time in series as
might be determined by the Company pursuant to the Senior Indenture and, in an unlimited aggregate principal amount; 
 WHEREAS, the Company
and the Trustee have entered into a First Supplemental Indenture, a Second Supplemental Indenture, a Third Supplemental Indenture, a Fourth Supplemental Indenture, a Fifth Supplemental Indenture, a Sixth Supplemental Indenture, a Seventh
Supplemental Indenture, an Eighth Supplemental Indenture, a Ninth Supplemental Indenture, a Tenth Supplemental Indenture, an Eleventh Supplemental Indenture, a Twelfth Supplemental Indenture, a Thirteenth Supplemental Indenture, a Fourteenth
Supplemental Indenture, a Fifteenth Supplemental Indenture, a Sixteenth Supplemental Indenture, a Seventeenth Supplemental Indenture, an Eighteenth Supplemental Indenture, a Nineteenth Supplemental Indenture , a Twentieth Supplemental Indenture, a
Twenty-First Supplemental Indenture, Twenty-Second Supplemental Indenture and Twenty-Third Supplemental Indenture providing for the creation and issuance of various series of Securities and/or amendments to the Senior Indenture (the Senior
Indenture, as so amended and supplemented by the forgoing supplemental indentures and this Supplemental Indenture is hereinafter referred to as, the “Indenture”); 

WHEREAS, Section 9.2 of the Senior Indenture provides that the Senior Indenture may be amended by the Company and the Trustee with the
consent of the holders of not less than a majority in aggregate principal amount of the outstanding Securities of all series affected by such amendment (all such series voting as a separate class); 

WHEREAS, the Company has distributed an Offer to Purchase and Consent Solicitation Statement, dated March 1, 2018 (the “Offer to
Purchase”), and accompanying consent and letter of transmittal to the holders of the 5.500% Senior Notes due 2024 (the “Notes”) in connection with certain proposed amendments to the Indenture with respect to the Notes as
described in the Offer to Purchase (the “Proposed Amendments”); 

 WHEREAS, the holders of at least a majority in principal amount of each series of the Notes
currently outstanding have duly consented to the Proposed Amendments , and the Company in accordance with Section 9.5 of the Senior Indenture, has delivered an Opinion of Counsel to the Trustee stating that the execution of this Supplemental
Indenture is permitted by the Indenture, that all requisite consents have been obtained, and that this Supplemental Indenture constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its
terms, subject to customary exceptions. 
 WHEREAS pursuant to Section 9.2 of the Senior Indenture, the Company desires to execute and
deliver this Supplemental Indenture, and has requested and hereby directs that the Trustee join with it in the execution and delivery of this Supplemental Indenture; and 

WHEREAS, the execution and delivery of this Supplemental Indenture have been duly authorized by all necessary corporate action on the part of
the Company and all conditions and requirements necessary to make this instrument a valid and binding agreement have been duly performed and complied with; 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Company and the Trustee mutually covenant and agree, for the benefit of each other and for equal and ratable benefit of the Holders of the Notes, as follows: 

ARTICLE 1 
 AMENDMENTS 

Section 1.01.    Amendments to the Indenture and Notes. 

(a)    The reference to “upon not less than 30 nor more than 60 days’ notice” in the first sentence of the
first paragraph of Section 3.2 of the Senior Indenture is hereby deleted and replaced with the following: “upon not less than three Business Days’ notice.” 

(b)    The reference to “third” prior to “Business Day” in the definition of “Comparable Treasury
Price” in the Seventeenth Supplemental Indenture shall be deleted. 
 (c)    The reference to “third”
prior to “Business Day” in the definition of “Reference Treasury Dealer Quotations” in the Seventeenth Supplemental Indenture shall be deleted. 

ARTICLE 2 
 MISCELLANEOUS 

Section 2.01.    Effect of Supplemental Indenture. From and after the Amendment Operative Date (as defined
below), the Indenture shall be amended and supplemented 

  
 3 

 
with respect to the Notes in accordance herewith, and this Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter
authenticated and delivered under the Indenture shall be bound thereby. 
 Section 2.02.    Indenture Remains in
Full Force and Effect. Except as amended and supplemented by this Supplemental Indenture, all provisions in the Indenture shall remain in full force and effect. 

Section 2.03.    References to Supplemental Indenture. Any and all notices, requests, certificates and other
instruments executed and delivered after the Amendment Operative Date may refer to the Indenture without making specific reference to this Supplemental Indenture, but nevertheless all such references shall include this Supplemental Indenture unless
the context requires otherwise. 
 Section 2.04.    Conflict with Trust Indenture Act. If any provision of
this Supplemental Indenture limits, qualifies or conflicts with any provision of the Trust Indenture Act of 1939 (the “TIA”) that is required under the TIA to be part of and govern any provision of this Supplemental Indenture, the
provision of the TIA shall control. If any provision of this Supplemental Indenture modifies or excludes any provision of the TIA that may be so modified or excluded, the provision of the TIA shall be deemed to apply to the Indenture as so modified
or to be excluded by this Supplemental Indenture, as the case may be. 
 Section 2.05.    Separability. In
case any provision in this Supplemental Indenture is invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby. 

Section 2.06.    Terms Defined in the Indenture. All capitalized terms not otherwise defined herein shall have
the meanings ascribed to them in the Indenture. 
 Section 2.07.    Headings. The headings of the Articles
and Sections of this Supplemental Indenture have been inserted for convenience of reference only, are not to be considered a part of the Indenture and in no way modify or restrict any of the terms and provisions of this Supplemental Indenture. 

Section 2.08.    Benefits of Supplemental Indenture. Nothing in this Supplemental Indenture or the Notes,
express or implied, shall give to any Person, other than the parties hereto and thereto and their successors hereunder and thereunder and the holders of the Notes any benefit of any legal or equitable right, remedy or claim under the Indenture, this
Supplemental Indenture or the Notes. 
 Section 2.09.    Successors. All agreements of the Company in this
Supplemental Indenture will bind its successors. All agreements of the Trustee in this Supplemental Indenture will bind its successors. 

Section 2.10.    Duplicate Originals. The parties may sign any number of copies of this Supplemental
Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental 

  
 4 

 
Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu
of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. 

Section 2.11.    Effectiveness. This Supplemental Indenture shall become a binding agreement between the
parties hereto when executed by the parties hereto. As used herein, the “Amendment Operative Date”, which is the date that the Proposed Amendments shall be operative, shall mean the date and time that the Company accepts the validly
tendered Notes for purchase pursuant to, and subject to the conditions set forth in, the Offer to Purchase. If, after the date hereof, either the Offer to Purchase is terminated or withdrawn or all payments in respect of the Notes accepted for
payment pursuant to the Offer to Purchase are not made as required by the Offer to Purchase, the Proposed Amendments shall have no effect and the Indenture shall be deemed to be amended so that it reads the same as it did immediately prior to the
date hereof. The Company shall provide prompt written notice to the Trustee if it accepts the Notes for purchase and remits payment pursuant to the Offer to Purchase, or if the Offer to Purchase is terminated or withdrawn or all payments in respect
of the Notes accepted for payment pursuant to the Offer to Purchase are not made. The Company shall cause Notes that have been purchased to be promptly delivered to the Trustee for cancellation pursuant to Section 2.11 of the Senior Indenture,
and the Trustee is hereby authorized and directed to cancel such Notes upon receipt. 
 Section 2.12.    Further
Instruments and Acts. Upon request of the Company, the Trustee will execute and deliver such further instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purpose of this Supplemental
Indenture. 
 Section 2.13.    Acceptance. The Trustee accepts the amendments of the Indenture effected by
this Supplemental Indenture, but on the terms and conditions set forth in the Indenture, including the terms and provisions defining and limiting the liabilities and responsibilities of the Trustee. Without limiting the generality of the foregoing,
the Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture or as to the accuracy of the recitals to this Supplemental Indenture. 

[Signature Page Follows] 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first above written. 
  

			
	THE AES CORPORATION, as the Issuer
		
	By:	 	 /s/ Daniel Stadelmann

	Name:	 	Daniel Stadelmann
	Title:	 	Vice President and Treasurer

  

			
	Attest:
		
	By:	 	 /s/ Thomas M. O’Flynn

	Name:	 	Thomas M. O’Flynn
	Title:	 	Executive Vice President and Chief Financial Officer

  

			
	DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee
	
	By: Deutsche Bank National Trust Company
		
	By:	 	 /s/ Jeffrey Schoenfeld

	Name:	 	Jeffrey Schoenfeld
	Title:	 	Vice President
		
	By:	 	 /s/ Irina Golovashchuk

	Name:	 	Irina Golovashchuk
	Title:	 	Vice President

  

			
	Attest:
		
	By:	 	 /s/ Chris Niesz

	Name:	 	Chris Niesz
	Title:	 	Assistant Vice President

  
 [Signature Page to the
Twenty-Fourth Supplemental Indenture]Exhibit 4.1

 

GOPHER
PROTOCOL INC.

 

STOCK WARRANT AGREEMENT

 

March 1, 2018

 

	Warrant Holder:	 	 	 	No. of Shares:	 	 

 

GOPHER PROTOCOL INC.,
a Nevada corporation (the “Company), hereby grants to the person identified above as the Warrant Holder a Warrant (the “Warrant”)
to purchase the number of shares set forth above, representing one share of common stock for every share of common stock subject
to an existing warrant exercised by such Warrant Holder. This Warrant is granted in consideration of the exercise of such existing
warrant and on the following terms and conditions:

 

1.       Exercise
of Warrant. Upon the execution of this Warrant, the shares of stock shall fully vest. Exercise of the Warrant is subject to
the following:

 

		a.	Exercise Price. The exercise price (the “Exercise Price”) shall be $1.85 per
Share.

 

		b.	Expiration of Warrant Term. The Warrant will expire at 5:00 p.m. Eastern Standard Time on
February 28, 2023, and may not be exercised thereafter (the “Expiration Date”).

 

		c.	Payment. The purchase price for Shares as to which the Warrant is being exercised shall
be paid in cash, by wire transfer, by certified or Company cashier’s check, or by personal check drawn on funds on deposit
with the Company.

 

		d.	Method of Exercise. The Warrant shall be exercisable by a written notice delivered to the
President or Secretary of the Company which shall:

 

		i.	State the owner’s election to exercise the Warrant, the number of Shares with respect to
which it is being exercised, the person in whose name the stock certificate for such Shares is to be registered, and such person’s
address and tax identification number (or, if more than one, the names, addresses and tax identification numbers of such persons);

 

		ii.	Be signed by the person or persons entitled to exercise the Warrant and, if the Warrant is being
exercised by any person or persons other than the original holder thereof, be accompanied by proof satisfactory to counsel for
the Company of the right of such person or persons to exercise the Warrant; and

 

		iii.	Be accompanied by the originally executed copy of this Stock Warrant Agreement.

 

     

     

    

 

		e.	Partial Exercise. In the event of a partial exercise of the Warrant, the Company shall either
issue a new agreement for the balance of the Shares subject to this Stock Warrant Agreement after such partial exercise, or it
shall conspicuously note hereon the date and number of Shares purchased pursuant to such exercise and the number of Shares remaining
covered by this Stock Warrant Agreement.

 

		f.	Restrictions on Exercise. The Warrant may not be exercised (i) if the issuance of the Shares
upon such exercise would constitute a violation of any applicable federal or state securities or Companying laws or other law or
regulation or (ii) unless the Company, the Company, or the holder hereof, as applicable, obtains any approval or other clearance
which the Company and the Company determine to be necessary or advisable from the Federal Reserve Board, the Federal Deposit Insurance
Corporation or any other state or federal Companying regulatory agency with regulatory authority over the operation of Company
or the Company (collectively the “Regulatory Agencies”). The Company may require representations and warranties from
the Warrant Holder as required to comply with applicable laws or regulations, including the Securities Act of 1933 and state securities
laws.

 

2.       Anti-Dilution;
Merger. If, prior to the exercise of the Warrant hereunder, the Company (i) declares, makes or issues, or fixes a record date
for the determination of holders of common stock entitled to receive, a dividend or other distribution payable on the Shares in
shares of its capital stock, (ii) subdivides the outstanding Shares, (iii) combines the outstanding Shares (including a reverse
stock split), (iv) issues any shares of its capital stock by reclassification of the Shares, capital reorganization or otherwise
(including any such reclassification or reorganization in connection with a consolidation or merger or and sale of all or substantially
all of the Company’s assets to any person), then the Exercise Price, and the number and kind of shares receivable upon exercise,
in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination or reclassification
shall remain fixed so that the holder of any Warrant exercised after such time shall be entitled to receive the number and kind
of shares which, if such Warrant had been exercised immediately prior to such time, he would have owned upon such exercise and
been entitled to receive.

 

3.       Valid
Issuance of Common Stock. The Company possesses the full authority and legal right to issue, sell, transfer, and assign this
Warrant and the Shares issuable pursuant to this Warrant. The issuance of this Warrant vests in the holder the entire legal and
beneficial interests in this Warrant, free and clear of any liens, claims, and encumbrances and subject to no legal or equitable
restrictions of any kind except as described herein. The Shares that are issuable upon exercise of this Warrant, when issued, sold
and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued,
fully paid, and non-assessable, and will be free of restrictions on transfer other than restrictions under applicable state and
federal securities.

 

4.       Compliance
with Securities Laws. This Agreement and the Warrant represented hereby were issued in reliance on an exemption from registration
under the Securities Act of 1933 (the “Act”) pursuant to Section 4(2) thereof, and other applicable exemptions under
state securities laws. The Company’s reliance on such exemption is predicated in part on the Warrant Holder’s representations
set forth herein. Warrant Holder understands that the Warrant and the Shares issuable upon exercise of the Warrant may not be sold,
transferred or otherwise disposed of without registration under the Securities Act of 1933, or an exemption therefrom, and that
in the absence of an effective registration statement covering such shares or an available exemption from registration under the
Securities Act, such Shares must be held indefinitely.

 

     

     

    

 

5.       Restrictions
on Transferability. This Agreement and the Warrant may not be assigned, transferred (except as provided above), pledged, or
hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment, or similar
process. Any attempted assignment, transfer, pledge, hypothecation, or other disposition of this Warrant contrary to the provisions
hereof shall be without legal effect. The Shares issuable on exercise of the Warrant may not be assigned or transferred by the
Warrant Holder without the Company’s prior written consent and, if so requested by the Company, the delivery by the Warrant
Holder to the Company of an opinion of counsel in form and substance satisfactory to the Company stating that such transfer or
assignment is in compliance with the Securities Act of 1933 and applicable state securities laws.

 

6.       Restrictive
Legend. Each certificate for Shares issued upon exercise of the Warrant shall bear a legend stating that they have not been
registered under the Securities Act of 1933 or any state securities laws and referring to the restrictions on transferability and
sale herein.

 

7.       Mandatory
Exercise; Termination.

 

		a.	Either the Company or the Company may be required to increase its capital to meet capital requirements
imposed by statute, rule, regulation, or guideline. In order to achieve such capital increase, the Regulatory Agencies may direct
the Company or the Company to require the Warrant Holders to either (i) exercise all or part of their Warrants or (ii) allow the
Warrants to be terminated. If the Regulatory Agencies so direct the Company or the Company, then the Warrant Holder must exercise
or forfeit this Warrant as set forth below.

 

		b.	When the Company or the Company is required to increase its capital as described in subsection
(a) above, the Company shall send a notice (the ‘‘Notice”) to the Warrant Holder (i) specifying the number of
Shares relating to the Warrant for which the Warrant must be exercised (the ‘‘Number”) (if less than all shares
relating to Warrant held by all holders of Warrant of the Company under agreements substantially similar to this one are required
by the Company to be exercised or cancelled, the Number for the Warrant Holder shall reflect a proportionate allocation based on
the number of Shares subject to this Agreement as compared to the total number of shares subject to Warrant held by all such warrant
holders as a group); (ii) specifying the date prior to which the Warrant must be totally or partially exercised, as the case may
be (the “Deadline”); (iii) specifying the Exercise Price for the Shares to be purchased pursuant to the Warrant (such
Exercise Price not to be less than current book value per share); and (iv) stating that the failure of the Warrant holder to exercise
the Warrant shall result in its automatic termination.

 

		c.	If the Warrant Holder does not exercise the Warrant pursuant to the terms of the Notice, this Agreement
shall be automatically terminated on the Deadline, without further act or action by the Warrant Holder or the Company, and the
Warrant Holder shall deliver this Agreement to the Company for cancellation. If the Number is less than the total number of Shares
that are then subject to exercise under this Agreement, the Company shall issue a new Stock Warrant Agreement in compliance with
Section l(e) hereof.

 

     

     

    

 

8.       Covenants
of the Company. During the term of the Warrant, the Company shall:

 

		a.	at all times authorize, reserve and keep available, solely for issuance upon exercise of this Warrant,
sufficient shares of common stock from time to time issuable upon exercise of this Warrant;

 

		b.	on receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
mutilation of this Warrant and, in the case of loss, theft, or destruction, on delivery of any indemnity agreement or bond reasonably
satisfactory in form and amount to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, at
its expense execute and deliver, in lieu of this Warrant, a new Warrant of like tenor; and

 

		c.	on surrender for exchange of this Warrant or any Warrant substituted therefor pursuant hereto,
properly endorsed, to the Company, at its expense, issue and deliver to or on the order of the holder thereof a new Warrant of
like tenor, in the name of such holder or as such holder (on payment by such holder of any applicable transfer taxes) may direct,
calling in the aggregate on the face or faces thereof for the issuances of the number of shares of common stock issuable pursuant
to the terms of the Warrant so surrendered.

 

9.       No
Dilution or Impairment. The Company shall not amend its Certificate of Incorporation or participate in any reorganization,
transfer of assets, consolidation, merger, dissolution, issuance or sale of securities or any other voluntary action for the purpose
of avoiding or seeking to avoid the observance or performance of any of the terms to be observed or performed hereunder by the
Company, but will at all times in good faith assist in carrying out all such action as may be reasonably necessary in order to
protect the exercise rights of the holder against improper dilution or other impairment.

 

10.       Amendment.
Neither this Agreement nor the rights granted hereunder may be amended, changed or waived except in writing signed by each party
hereto.

 

IN WITNESS WHEREOF,
the Company has executed and the holder has accepted this Stock Warrant Agreement as of the date and year first above written.

 

	 	GOPHER PROTOCOL INC.
	 	 	 
	 	By:	 
	 	 	President
	 	 	 
	 	Attest:	 
	 	 	Secretary

 

(CORPORATE SEAL)

 

	 	WARRANT HOLDER:
	 	 	 
	 	By:	 
	 	 	Signature
	 	 	 
	 		 
	 	 	Print Name

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]